News
NLTX
--
0.00%
--
Insider Buying: The Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) CEO, President & Director Just Bought 2.3% More Shares
Potential Neoleukin Therapeutics, Inc. ( NASDAQ:NLTX ) shareholders may wish to note that the CEO, President...
Simply Wall St. · 06/08 05:56
Insider Trends: 90-Day Buying Trend Prolonged with Insider Purchase of Neoleukin Therapeutics Stock
MT Newswires · 06/07 17:14
The Daily Biotech Pulse: Merck, AstraZeneca, Novartis Among Early Presenters At ASCO, Sanofi Strikes Breast Cancer Study Pact
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 3)
Benzinga · 06/04 13:39
The Daily Biotech Pulse: Merck Completes Organon Spin-Off, Auris Repositions As RNA Therapeutic Company With Trasir Purchase, Replimune's Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 2)
Benzinga · 06/03 12:23
Neoleukin Therapeutics to Participate in Jefferies Virtual Healthcare Conference
Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will present a...
GlobeNewswire · 05/26 12:09
Is Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) Popular Amongst Insiders?
A look at the shareholders of Neoleukin Therapeutics, Inc. ( NASDAQ:NLTX ) can tell us which group is most powerful...
Simply Wall St. · 05/17 14:29
Neoleukin Therapeutics Announces First Quarter 2021 Financial Results and Corporate Update
- Entered clinical development with first patient dosed in Phase 1 Trial of NL-201 - - Appointed Priti Patel, M.D., as Chief Medical Officer - - Cash and cash equivalents of $178.4 million expected to fund operations into 2023 - SEATTLE, May 12, 2021 (GLOB...
GlobeNewswire · 05/12 12:47
Neoleukin Therapeutics EPS misses by $0.04
Neoleukin Therapeutics (NLTX): Q1 GAAP EPS of -$0.27 misses by $0.04.Cash and cash equivalents of $178.39M.Press Release
Seekingalpha · 05/12 12:21
BRIEF-Neoleukin Therapeutics Says Entered Clinical Development With First Patient Dosed In Phase 1 Trial Of Nl-201
reuters.com · 05/12 12:16
10-Q: NEOLEUKIN THERAPEUTICS, INC.
(EDGAR Online via COMTEX) -- Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations You should read the following...
Edgar Online - (EDG = 10Q, 10K) · 05/12 12:09
Neoleukin Therapeutics Q1 Loss Widens, Operating Expenses Rise
MT Newswires · 05/12 08:58
Neoleukin Therapeutics Announces Initiation of Phase 1 NL-201 Trial
GlobeNewswire · 05/05 13:00
BRIEF-Neoleukin Therapeutics Announces Initiation Of Phase 1 NL-201 Trial
reuters.com · 05/05 12:04
Neoleukin Therapeutics to Participate in BofA Securities 2021 Healthcare Conference
SEATTLE, May 04, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D...
GlobeNewswire · 05/04 13:00
Analysts Offer Insights on Healthcare Companies: Neoleukin Therapeutics (NLTX) and Sol-Gel Technologies (SLGL)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Neoleukin Therapeutics (NLTX) and Sol-Gel Technologies
SmarterAnalyst · 04/28 10:25
Ne­oleuk­in's IL-2 Agonist Candidate Cleared To Start Phase 1 Trial In Solid Tumors
Benzinga · 04/26 14:19
Neoleukin Therapeutics (NLTX) Gets a Buy Rating from Mizuho Securities
Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Neoleukin Therapeutics (NLTX) today and set a price target of $21.00. The company's
SmarterAnalyst · 04/26 13:15
Neoleukin Therapeutics Announces Clearance To Proceed With NL-201 Phase 1 Clinical Trial In United States
Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that the U.S.
Benzinga · 04/26 11:03
Neoleukin Therapeutics' Drug Greenlit for Phase 1 Trial as US FDA Lifts Clinical Hold
MT Newswires · 04/26 08:24
10 Cheap Pharmaceutical Stocks For 2021
In this article we will take a look at the 10 cheap pharmaceutical stocks for 2021. You can skip our comprehensive analysis of the pharma industry and go directly to the 5 Cheap Pharmaceutical Stocks For 2021. Pharmaceutical companies have been in the spot...
Insider Monkey · 04/17 13:20
Webull provides a variety of real-time NLTX stock news. You can receive the latest news about Neoleukin Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About NLTX
Neoleukin Therapeutics, Inc., formerly Aquinox Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is focused on the development and commercialization of computationally-designed protein therapeutics to address unmet medical needs in immuno-oncology, inflammation, and autoimmunity. Its computational platform allows it to design new de novo proteins to treat serious diseases, including cancer, inflammatory, and autoimmune disorders. Its lead program, NL-201, is a computationally-designed de novo protein therapeutic. NL-201 is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. NL-201 is designed for use as a single-agent or in combination with complementary therapeutic modalities.